Patents Assigned to XenoPort
  • Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use
    Patent number: 7777070
    Abstract: Acyloxyalkyl carbamate prodrugs of trans-4-(aminomethyl)-cyclohexanecarboxylic acid, pharmaceutical compositions thereof, methods of making prodrugs of trans-4-(aminomethyl)-cyclohexane-carboxylic acid, and methods of using prodrugs of trans-4-(aminomethyl)-cyclohexanecarboxylic acid and pharmaceutical compositions thereof to treat or prevent various diseases or disorders are disclosed. Acyloxyalkyl carbamate prodrugs of trans-4-(aminomethyl)-cyclohexanecarboxylic acid and pharmaceutical compositions thereof suitable for oral and topical administration and for administration using sustained release dosage forms are also disclosed.
    Type: Grant
    Filed: August 14, 2009
    Date of Patent: August 17, 2010
    Assignee: XenoPort, Inc.
    Inventors: Noa Zerangue, Bernd Jandeleit, Yunxiao Li, Mark A. Gallop
  • LEVODOPA PRODRUGS, AND COMPOSITIONS AND USES THEREOF
    Publication number: 20100197953
    Abstract: Prodrugs of levodopa, methods of making prodrugs of levodopa, methods of using prodrugs of levodopa, and compositions of prodrugs of levodopa are disclosed.
    Type: Application
    Filed: February 2, 2009
    Publication date: August 5, 2010
    Applicant: XenoPort, Inc.
    Inventors: Jia-Ning Xiang, Mark A. Gallop, Cindy X. Zhou, Mark Nguyen, Xuedong Dai, Jianhua Li, Kenneth C. Cundy, Nelson L. Jumbe
  • Amino acid conjugates providing for sustained systemic concentrations of GABA analogues
    Patent number: 7767649
    Abstract: This invention is directed to compounds that provide for sustained systemic concentrations of GABA analogs following administration to animals. This invention is also directed to pharmaceutical compositions including and methods using such compounds.
    Type: Grant
    Filed: January 18, 2007
    Date of Patent: August 3, 2010
    Assignee: XenoPort, Inc.
    Inventors: Randall A. Scheuerman, Mark A. Gallop, Kenneth C. Cundy, Ronald W. Barrett
  • LEVODOPA DIMETHYL-SUBSTITUTED DIESTER PRODRUGS, COMPOSITIONS, AND METHODS OF USE
    Publication number: 20100173992
    Abstract: Levodopa dimethyl-substituted diester prodrugs pharmaceutical, compositions comprising levodopa dimethyl-substituted diester prodrugs, and methods of using such prodrugs and pharmaceutical compositions for treating diseases such as Parkinson's disease are provided.
    Type: Application
    Filed: March 18, 2010
    Publication date: July 8, 2010
    Applicant: XenoPort, Inc.
    Inventors: Jia-Ning Xiang, Cindy X. Zhou, Fenmei Yao, Mark Q. Nguyen
  • Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
    Patent number: 7749985
    Abstract: Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphinic acid and analogs thereof, methods of making acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphinic acid and analogs thereof, methods of using acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphinic acid and analogs thereof, and pharmaceutical compositions comprising acyloxyalkyl carbamate prodrugs 3-aminopropylphosphinic acid and analogs thereof for treating diseases or disorders such as mild cognitive impairment, cognitive impairment associated with Alzheimer's disease Alzheimer's disease, depression, anxiety, and epilepsy are disclosed. Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphinic acid and analogs thereof, which are suitable for oral administration and sustained release oral dosage forms are also disclosed.
    Type: Grant
    Filed: July 21, 2009
    Date of Patent: July 6, 2010
    Assignee: XenoPort, Inc.
    Inventors: Mark A. Gallop, Feng Xu, Thu Phan, Usha Dilip, Ge Peng
  • TREATING AND/OR PREVENTING URINARY INCONTINENCE USING PRODRUGS OF GABA ANALOGS
    Publication number: 20100166825
    Abstract: Disclosed herein are methods of using prodrugs of GABA analogs and pharmaceutical compositions thereof to treat and/or prevent urinary incontinence in humans, and pharmaceutical compositions of prodrugs of GABA analogs useful in treating and/or preventing urinary incontinence.
    Type: Application
    Filed: March 9, 2010
    Publication date: July 1, 2010
    Applicant: XenoPort, Inc.
    Inventor: Ronald W. Barrett
  • Epitope-captured antibody display
    Patent number: 7741062
    Abstract: Reagents and methods for detecting target proteins in a sample are provided. The reagents include a replicable genetic package, a protein displayed on an exterior surface of the package that is expressed from a heterologous nucleic acid borne by the package, and one or more antibodies complexed with the expressed protein and which have an open binding site for a target protein. Thus, a segment of the nucleic acid encodes for an epitope that is shared by the expressed polypeptide and the target protein. The reagents can be utilized individually or as part of a library or an array to bind target proteins within protein samples to form one or more complexes. By determining the sequence of the segment of the heterologous nucleic acid of a package within a complex, one can identify the target protein since the segment encodes for an epitope that is shared by the expressed and target proteins.
    Type: Grant
    Filed: April 7, 2009
    Date of Patent: June 22, 2010
    Assignee: XenoPort, Inc.
    Inventors: William J. Dower, Steven E. Cwirla
  • Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment
    Publication number: 20100137442
    Abstract: Sustained release particulate oral dosage forms of (R)-baclofen prodrugs and methods of treating a disease comprising orally administering such dosage forms are disclosed.
    Type: Application
    Filed: February 1, 2008
    Publication date: June 3, 2010
    Applicant: XenoPort, Inc.
    Inventors: Srikonda SASTRY, Kenneth CUNDY, Manshiu LEUNG
  • CREATINE PHOSPHATE ANALOG PRODRUGS, COMPOSITIONS AND USES THEREOF
    Publication number: 20100137255
    Abstract: Membrane permeable prodrugs of creatine phosphate analogs, pharmaceutical compositions comprising membrane permeable prodrugs of creatine phosphate analogs, and methods of treating diseases such as ischemia, heart failure, and neurodegenerative disorders comprising administering prodrugs of creatine phosphate analogs, or pharmaceutical compositions thereof are disclosed.
    Type: Application
    Filed: February 3, 2010
    Publication date: June 3, 2010
    Applicant: XenoPort, Inc.
    Inventors: Noa Zerangue, Qingzhi Gao, William J. Dower
  • Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
    Patent number: 7727976
    Abstract: Disclosed are compounds that exhibit high transport across the intestinal wall of an animal. The compounds may optionally be linked to drugs that are poorly absorbed or poorly transported across the intestinal wall after oral administration to provide for enhanced therapeutic, and optionally prolonged therapeutic, systemic blood concentrations of the drugs upon oral administration of the drug-compound conjugate. Also disclosed are pharmaceutical compositions containing and methods of using such compounds.
    Type: Grant
    Filed: September 26, 2005
    Date of Patent: June 1, 2010
    Assignee: XenoPort, Inc.
    Inventors: Laxminarayan Bhat, Mark A. Gallop, Bernd Jandeleit
  • Levodopa dimethyl-substituted diester prodrugs compositions, and methods of use
    Patent number: 7709527
    Abstract: Levodopa dimethyl-substituted diester prodrugs pharmaceutical, compositions comprising levodopa dimethyl-substituted diester prodrugs, and methods of using such prodrugs and pharmaceutical compositions for treating diseases such as Parkinson's disease are provided.
    Type: Grant
    Filed: December 20, 2007
    Date of Patent: May 4, 2010
    Assignee: XenoPort, Inc.
    Inventors: Jia-Ning Xiang, Cindy X. Zhou, Fenmei Yao, Mark Q. Nguyen
  • Screening of compounds for OCTN2 transporter activity
    Patent number: 7704696
    Abstract: OCTN2 is consistently expressed at high levels in brain microvessel endothelial cells. Disclosed herein are assays for determining whether a test material/molecule is a substrate for, and/or is actively transported by, the OCTN2 transporter, and therefore a candidate substrate for crossing the blood brain barrier. The assays are useful in screening for therapeutic, cytotoxic or imaging compounds used in the treatment or diagnosis of neurological diseases.
    Type: Grant
    Filed: July 25, 2006
    Date of Patent: April 27, 2010
    Assignee: XenoPort, Inc.
    Inventor: Noa Zerangue
  • Screening of compounds for BGT1 transporter activity
    Patent number: 7704695
    Abstract: BGT1 is consistently expressed at high levels in brain microvessel endothelial cells. Disclosed herein are assays for determining whether a test material/molecule is a substrate for, and/or is actively transported by, the BGT1 transporter, and therefore a candidate substrate for crossing the blood brain barrier. The assays are useful in screening for therapeutic, cytotoxic or imaging compounds used in the treatment or diagnosis of neurological diseases.
    Type: Grant
    Filed: July 25, 2006
    Date of Patent: April 27, 2010
    Assignee: XenoPort, Inc.
    Inventor: Noa Zerangue
  • Screening of compounds for GAT2 transporter activity
    Patent number: 7700300
    Abstract: GAT2 is consistently expressed at high levels in brain microvessel endothelial cells. Disclosed herein are assays for determining whether a test material/molecule is a substrate for, and/or is actively transported by, the GAT2 transporter, and therefore a candidate substrate for crossing the blood brain barrier. The assays are useful in screening for therapeutic, cytotoxic or imaging compounds used in the treatment or diagnosis of neurological diseases.
    Type: Grant
    Filed: July 25, 2006
    Date of Patent: April 20, 2010
    Assignee: XenoPort, Inc.
    Inventor: Noa Zerangue
  • Treating urinary incontinence using prodrugs of GABA analogs
    Patent number: 7700652
    Abstract: Disclosed herein are methods of using prodrugs of GABA analogs and pharmaceutical compositions thereof to treat and/or prevent urinary incontinence in humans, and pharmaceutical compositions of prodrugs of GABA analogs useful in treating and/or preventing urinary incontinence.
    Type: Grant
    Filed: September 13, 2004
    Date of Patent: April 20, 2010
    Assignee: XenoPort, Inc.
    Inventor: Ronald W. Barrett
  • METHODS OF SYNTHESIZING 1-(ACYLOXY)-ALKYL CARBAMATE PRODRUGS
    Publication number: 20100087667
    Abstract: The present disclosure relates to methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs and to intermediates used in the methods.
    Type: Application
    Filed: August 7, 2009
    Publication date: April 8, 2010
    Applicants: XenoPort, Inc., Glaxo Group Limited
    Inventors: Stephen P. Raillard, Suresh K. Manthati, Peng Liu, Qunying Dai, Hao Yin
  • AMINO ACID DERIVED PRODRUGS OF PROPOFOL, COMPOSITIONS, USES AND CRYSTALLINE FORMS THEREOF
    Publication number: 20100087536
    Abstract: The present invention provides a prodrug of propofol and crystalline forms thereof, methods of making the propofol prodrug and crystalline forms thereof, pharmaceutical compositions of the propofol prodrug and crystalline forms thereof, methods of using the propofol prodrug and crystalline forms thereof and pharmaceutical compositions thereof to treat diseases or disorders such as headache pain, post-chemotherapy or post-operative surgery nausea and vomiting, neurodegenerative disorders, and mood disorders.
    Type: Application
    Filed: October 2, 2009
    Publication date: April 8, 2010
    Applicant: XenoPort, Inc.
    Inventors: Feng Xu, Mark A. Gallop, Vivek Sasikumar, Usha Dilip
  • Screening of compounds for OCT3 transporter activity
    Patent number: 7691584
    Abstract: OCT3 is consistently expressed at high levels in brain microvessel endothelial cells. Disclosed herein are assays for determining whether a test material/molecule is a substrate for, and/or is actively transported by, the OCT3 transporter, and therefore a candidate substrate for crossing the blood brain barrier. The assays are useful in screening for therapeutic, cytotoxic or imaging compounds used in the treatment or diagnosis of neurological diseases.
    Type: Grant
    Filed: July 25, 2006
    Date of Patent: April 6, 2010
    Assignee: XenoPort, Inc.
    Inventor: Noa Zerangue
  • METHODS OF SYNTHESIZING N-HYDROXYSUCCINIMIDYL CARBONATES
    Publication number: 20100081830
    Abstract: The present disclosure relates to methods of synthesizing N-hydroxysuccinimidyl-carbonate intermediates from the corresponding sulfones useful in the preparation of 1-(acyloxy)-alkyl carbamate prodrugs.
    Type: Application
    Filed: August 7, 2009
    Publication date: April 1, 2010
    Applicants: XenoPort, Inc., Glaxo Group Limited
    Inventors: Stephen P. Raillard, Suresh K. Manthati, Peng Liu, Qunying Dai, Hao Yin
  • Creatine phosphate analog prodrugs, compositions and uses thereof
    Patent number: 7683043
    Abstract: Membrane permeable prodrugs of creatine phosphate analogs, pharmaceutical compositions comprising membrane permeable prodrugs of creatine phosphate analogs, and methods of treating diseases such as ischemia, heart failure, and neurodegenerative disorders comprising administering prodrugs of creatine phosphate analogs, or pharmaceutical compositions thereof are disclosed.
    Type: Grant
    Filed: June 6, 2007
    Date of Patent: March 23, 2010
    Assignee: XenoPort, Inc.
    Inventors: Noa Zerangue, Qingzhi Gao, William J. Dower